Scalper1 News
Several analysts initiated coverage on Global Blood Therapeutics (GBT), which rates among the top five IPOs this year after popping more than 100% on its first day of trading and touched a new high of 57 in early trading Tuesday. Morgan Stanley initiated coverage with an overweight rating and a price target of 67. Analyst Mathew Harrison, in the research report, said Global Blood Therapeutics offers “a potentially transformative sickle cell Scalper1 News
Scalper1 News